Fairvalue-Calculator Fairvalue-Calculator
EN DE

Sinphar Pharmaceutical Co (1734) Fair Value & Analysis

Healthcare · TW · Market cap 5.9B TWD

Price32.30 TWD
Fair Value35.82 TWD
Upside+10.9%
Quality89/100
Evidence: Medium Range 22.92 TWD – 51.41 TWD

Fair value as of: Jun 24, 2026

Analysis

Sinphar Pharmaceutical Co (1734) currently trades at 32.30 TWD, while our model-based Fair Value estimate is 35.82 TWD — implying the stock looks roughly 10.9% undervalued today. We read business quality at 89/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium) — always confirm before acting.

About the company

Sinphar Pharmaceutical Co.,Ltd., together with its subsidiaries, engages in the production, processing, selling, and trading of various medicines, Chinese medicines, medical cosmetic products and nutrients in Taiwan, Mainland China, Vietnam, Indonesia, and internationally. It operates through three segments: Pharmaceuticals, Healthy Food, and Others. The company offers pharmaceutical products, including antineoplastic, ophthalmic, ENT, oral, respiratory system, dermatology, analgesic and NSAIDs, metabolic and nutrient, gastrointestinal, and other products; and healthy food under the Sinphar, DailyCare, Migus, YouBest, and SynCoreBio brands. It also provides moisturizer repair essence, anti aging cream, renewable oi, and UV defence cream under the DYNASKIN brand; serum, revitalizing cream, hygiene, sunblock, sunscreen, and lightening tables under the Yestuner brand; and shower gel and hair shampoo. In addition, the company is involved in the provision of testing and development, as w…

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -38% Regeneron Pharmaceuticals, Inc (REGN) -14% UCB SA (UCB) -27% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) -28% Alnylam Pharmaceuticals, Inc (ALNY) -63%

Frequently asked questions

Is Sinphar Pharmaceutical Co (1734) undervalued?
As of Jun 24, 2026, our model estimates a fair value of 35.82 TWD versus a price of 32.30 TWD — about +11% (undervalued). Model-based estimate, not financial advice.
What is the fair value of 1734?
Our 21-model fair value for Sinphar Pharmaceutical Co is 35.82 TWD (as of Jun 24, 2026), built from audited fundamentals. The current price is 32.30 TWD.
What is the quality score of 1734?
Sinphar Pharmaceutical Co has a Quality Score of 89/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.